Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.1.3-03 | Award Amount: 12.00M | Year: 2013
Production diseases compromise health and welfare, generating inefficiencies which impact adversely on profitability, environmental footprint, antibiotic use and product quality. The PROHEALTH project will develop understanding of the multi-factorial dimension of animal pa-thologies linked to the intensification of production and use this to develop, evaluate and disseminate ef-fective control strategies to reduce impact. It will address production diseases of pigs and poultry raised in a wide range of EU intensive systems, using both epidemiological and experimental approaches to consider the extent of, and the risk factors associated with diseases, the influence of genotype and its modification by early life experience, and the dynamic influences of the environment on disease. The mechanisms underlying differences in disease susceptibility will be explored at different levels. Improvement strategies for diseases including neo-natal mortality, gut and respiratory disorders, leg and metabolic disorders will be evaluated in farm scale tests, and data from diverse systems used to model whole-chain socioeconomic implications of disease states and their alleviation. The consortium has expertise in veterinary science and epidemiology, physiology and immunology, ge-netics, nutrition, socioeconomics, welfare and production science of pigs and poultry. The 10 academic, 1 association 4 industry and 7 SME partners cover the full European geographic range to derive meaningful epidemiological data and test interventions across diverse production circumstances. Dissemination activities will encompass all stakeholders in the food chain and establish new e-learning tools. PROHEALTH will deliver novel diagnostics for the propensity to develop production diseases and their occurrence, and multifactorial improvement strategies that can be applied to produce better quality products in a welfare friendly manner and improve competitiveness and sustainability of EU pig & poultry systems
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.1.2-10 | Award Amount: 8.06M | Year: 2012
European aquaculture production provides direct employment to 65.000 people with a turnover of 3 billion . However, the lack of authorised veterinary medicinal products and the consequent disease outbreaks in farmed fish species costs the sector 20% of the production value. The most appropriate method for disease control, both on economical and ethical grounds, is disease prevention by vaccination. TargetFish will advance the development of existing (but not sufficient) and new prototype vaccines against socio-economically important viral or bacterial pathogens of Atlantic salmon, rainbow trout, common carp, sea bass, sea bream and turbot. The project will develop targeted vaccination strategies for currently sub-optimal and for novel vaccines. Improved vaccines will be brought closer to industrial application by addressing practical issues such as efficacy, safety and delivery route. TargetFish will also establish a knowledge- and technology-base for rational development of next generation fish vaccines. To achieve these challenging tasks, we brought together 29 partners from 11 EU member states, 2 associated countries and 1 International Cooperation Partner Country (ICPC). In this large multidisciplinary consortium an approximate equal number of RTD and SME partners will cooperate closely while keeping an intensive communication with the large vaccine and nutrition industries via an Industry Forum. Specifically, TargetFish will 1) generate knowledge by studying antigens and adjuvants for mucosal routes of administration while analyzing the underpinning protective immune mechanisms; 2) validate this knowledge with response assays for monitoring vaccine efficacy and study safety aspects, including those associated with DNA vaccines; 3) approach implementation of prototype vaccines by optimizing vaccination strategies thus 4) shortening the route to exploitation. Thereby, this project will greatly enhance targeted disease prophylaxis in European fish farming.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: KBBE.2010.2.4-01 | Award Amount: 3.49M | Year: 2012
The general objectives of PROMISE are: PROMISE strives for multidimensional networking thus fostering integration The primary strategic objective of PROMISE is to improve and increase the integration, collaboration and knowledge transfer between the new member states, old member states (EU15) and candidate countries through a collaborative workplan of exchange of expertise and regional training and dissemination actions, to tackle common food safety threats. PROMISE strives for sustainability through involvement of risk communicators A further strategic objective is to integrate stakeholders like public health authorities and national food safety authorities from the old and new member countries in order to ensure the exploitation of research results into standardisation and harmonisation efforts. PROMISE will enhance the knowledge on pathogen transmission While legal imports are well monitored for contamination and alerts are registered through the Rapid Alert System for Food and Feed (RASFF; http://www.efet.gr/docs/rasff/report2008_en.pdf) notification systems, gates into the EU-27 could exist where food supply chains are not controllled. These uncontrolled imports present the risk that new strains of traditional pathogens will be transferred from third countries into the European Union. Analysing, assessing and interpreting this risk of introducing new strains of pathogens is one of the main objectives of PROMISE.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.1.2-10 | Award Amount: 7.96M | Year: 2014
Only about 10% of todays global aquaculture production use genetically improved stocks. In Europe, some breeding programmes consist of only the basic components of a breeding scheme. Hence, there is large potential to increase efficiency and profit by domestication and genetic improvement of farmed finfish. The main challenge of FISHBOOST is to realise this potential into economic and social acceptable breeding schemes, and advance these for each of the six target species. Acknowledging the different capacities of the species, the aim of FISHBOOST is: To improve the efficiency and profitability of European aquaculture by advancing selective breeding to the next level for each of the six main finfish species through collaborative research with industry. FISHBOOST considers the main components of breeding programmes for Atlantic salmon, common carp, European seabass, gilthead seabream, rainbow trout and turbot. Disease resistance and production efficiency are genetically improved through detailed phenotyping and advanced genomic technologies. The economic impact and producers perceptions will be assessed for the recommendations for each of the species. 14 well-recognised RTD participants in Europe on aquaculture breeding will collaborate in a five year comprehensive research project with 7 SMEs, 4 large industries and 1 NGO throughout Europe that are in the lead of the development of their species breeding programmes or are vectors between industry and RTD. A mixture of low and high-tech technological advances depending on current capacities of the species will be developed to move each species breeding program to the next level. This step-change advance will facilitate balanced and sustainable breeding programmes applying a wide set of traits, breeding tools and technologies. A dissemination program will deliver these results to SMEs and other end-users, thereby advancing existing and stimulating new aquaculture breeding programmes in Europe.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: KBBE-2007-2-4-03 | Award Amount: 3.87M | Year: 2008
The concept of VITAL is the integrated monitoring and control of contamination of the European food supply chain by pathogenic viruses. VITAL will use advanced methods for virus detection throughout selected food supply chains from farm to market, to gather data on virus contamination of food and environmental sources suitable for quantitative viral risk assessment. Supply chains will be monitored for the presence of indicator viruses commonly found in faecal contamination events. These viruses can be distinguished into strains of human and animal origin, which will indicate contamination from a specific source. Modelling tools will be developed to define the quantitative viral risk for each scenario, and to assess foodborne viral risks for determining high risk situations and efficacy of interventions. Modular process risk models will be developed to build up specific HACCP recommendations. Recent developments in risk management will be evaluated for their use in reducing foodborne viral infections. Survival of viruses in foods will be modelled, and disinfection procedures used in the food industry will be evaluated, to elucidate the critical points where virus contamination may be controlled. VITAL will disseminate its findings by producing handbooks and guidelines on appropriate control practices, and communicate requirements necessary for establishing reliable monitoring of food chains for viruses on a regular or as-needed basis. Therefore VITAL will provide to Europe a framework for monitoring, risk modelling, and procedures for control of foodborne virus contamination, which will be applicable to any virus, whether existing, emerging or re-emerging, that poses the danger of being transmitted by food. Implementation of such a framework of preventive or proactive virus contamination management will form a first line of defence against transmission of foodborne viral diseases in Europe.
Stecova J.,Masaryk University |
Kaevska M.,Vyzkumny Ustav Veterinarniho Lekarstvi
Hygiena | Year: 2015
Unrestricted access to drinking water of good quality is one of the basic prerequisite of life. For this to be achieved it is necessary to treat the raw water through chemical, biological and physical methods. However, the water treatment is not exhaustive and some microorganisms are able to overcome it whereby posing a health risk. This review draws attention mainly to the occurrence of free living amoeba at different stages of water treatment and their importance as a reservoir of potentially pathogenic non-tuberculous mycobacteria. Mycobacteria may present a severe threat to human health considering they cause serious infections to the skin, as well as of the respiratory and gastrointestinal systems.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.4-1 | Award Amount: 4.07M | Year: 2013
The overall aim of ASKLEPIOS is to unravel and increase our understanding of the mechanisms that govern pathogenesis of rabies virus (RABV) infection, in pursuit of the rational identification of novel therapeutic leads for rabies encephalitis. Several studies have been conducted over the past decades attempting to unravel the pathogenesis of this deadly disease, however with limited success. New knowledge on the mechanisms of the RABV life-cycle and interaction with the host is needed to identifying clinically applicable therapeutic leads, in search of rational intervention strategies. The project objectives are to: 1. Identify molecules that inhibit RABV replication 2. Identify molecules that inhibit detrimental host responses to RABV infection: 3. Show whether opening the blood-brain-barrier (BBB) improves treatment efficacy: 4. Validate the potential of the molecules identified under 1 and 2 to be used as post-exposure prophylaxis (PEP) when classical PEP is ineffective. In pursuit of these objectives ASKLEPIOS will perform in vitro screening of the anti-viral effect of type-I IFNs, MAP kinase inhibitors and siRNAs. Second, the therapeutic potential of inhibiting the pyroptotic pathway and inflammatory response will be investigated by using inhibitors of caspase-1, IL-1, TNF- IL-6 and MAP kinases. Third, the capacity of molecules to reach the brain will be first evaluated using an efficient in vitro BBB system and in vivo mouse studies.. The most efficient molecule to open the BBB will be co-administrated with the selected therapeutic molecules in the subsequent stages of the project. The results will be collected and synthesized and tested in mice to identify the most effective approach. The ability to clear infection and recover from rabies will be evaluated for each therapeutic scheme identified
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: ENV.2008.1.2.1.4. | Award Amount: 3.53M | Year: 2009
Chlorinated dioxins and biphenyls (PCBs) commonly occur in the human food chain and can still be detected at levels that might cause long term health effects. Exposure to dioxin-like compounds involves a complex mixture with a common mechanism of action involving endocrine, developmental, carcinogenic, immuno and neurological effects. Risk assessment is done with an additive model for mixture toxicity. Based on this the Toxic Equivalency (TEQ) concept was developed as a biomarker for exposure and risk. TEQs are the sum of congener-specific toxic equivalency factors (TEFs) multiplied by the concentration in a matrix, e.g. blood. TEF values are a composite quantitative value from a range of biomarkers that are congener and endpoint specific. Present human TEQs have been derived from oral administration experiments providing intake TEFs. Regulatory authorities frequently use intake TEQs for blood and tissues considering it a biomarker for exposure or effect. Experimental evidence shows that using uptake TEQs as systemic biomarkers may lead to misinterpretation of risks. Therefore, development and validation of systemic TEFs and TEQs as biomarkers is necessary. Major objectives of SYSTEQ are: i) establish systemic TEFs and TEQs, ii) identify novel quantifiable biomarkers with newest molecular methods, e.g. genetic fingerprinting profiles, iii) extra focus on effects in peripheral lymphocytes as biomarkers, iv) identify differences between humans and experimental species. The systemic TEFs and TEQs from SYSTEQ will be used in conjunction with results of the completed EU PCBRISK project, in which two populations from Slovakia with very different exposure were studied. Individual blood levels and different biomarkers are already available. Results of SYSTEQ are also going to be used to establish international consensus values of systemic TEFs at WHO level, facilitating the global use of systemic TEQs as biomarkers of effect and exposure.
Moutelikova R.,Vyzkumny ustav veterinarniho lekarstvi |
Prodelalova J.,Vyzkumny ustav veterinarniho lekarstvi
Epidemiologie, Mikrobiologie, Imunologie | Year: 2015
Rotaviruses are significant enteric pathogens of humans and animals. Rotavirus-associated mortality is still high in children, especially in developing countries. Rotaviruses also account for important economic losses due to gastrointestinal disease of livestock animals, notably of young cattle and pigs. Increasing numbers of different rotavirus strains stress the necessity of their uniform nomenclature and detailed classification with the use of whole-genome sequencing. Phylogenetic analyses of the rotavirus genome reveal repeated intersections between the evolution of human and animal rotavirus strains which is probably a consequence of multiple events of transmission among various animal species. The interspecies transmission and subsequent gene reassortment are important mechanisms driving the diversity of rotaviruses and enabling the emergence of new pathogenic strains. © 2015, Czech Medical Association J.E. Purkyne. All rights reserved.
Vyzkumny Ustav Veterinarniho Lekarstvi and Ustav Organicke Chemie A Biochemie Av Cr | Date: 2013-01-14
The invention provides new lipopolyamines of spermine type of the general formula I, wherein X is CN bond or aminopolyethyleneglycolcarboxamide linker or o-hydroxy-alkylcarboxamide linker or -hydroxyalkylcarboxamidopolyethyleneglycol-carboxamide linker, and wherein a hydrophobic domain Y is an acyl symmetrically branched in the position C(2) or cholesteryl. The invention further provides a method of preparation of said lipopolyamines and their use for construction of polycationic liposomal drug carriers.